Floatz logo

Nivolumab

Recurrent Head and Neck Carcinoma

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Recurrent Head and Neck Carcinoma cohort.

Asset / SponsorPhaseRating
Cediranib
National Cancer Institute (NCI)
Phase 1CCC
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Mayo Clinic
Phase 1CC
mk-3475
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 1CC
FLUOROURACILUM
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 1CC
Eloxatin
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 1CC

View all 9 →

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →